Floatz logo

DOTATOC

Neuroblastoma

Sue O'Dorisioprotein_peptidePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

63 Active assets in the Neuroblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 2/3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 4BB
Cyclophosphamide
Robbie Majzner
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

DOTATOC is also rated in:

digestive system neuroendocrine neoplasmDormant
B
Indicative ·
63 / 100
View asset →
carcinoid tumorDormant
B
Indicative ·
59 / 100
View asset →
neuroendocrine neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →